p-SCN-Macropa

p-SCN-macropa conjugates to Nimotuzumab (HY-P9968) and Rituximab (HY-P9913) with high purity, forming macropa-Nimotuzumab with an estimated 3 p-SCN-macropa molecules per antibody^[1].
p-SCN-Macropa-derived[²²⁵Ac]Ac-macropa-Nimotuzumab potently inhibits viability of 2D monolayer cultures of DLD-1 (IC₅₀ 1.8 nM), SNU-C2B (IC₅₀ 3.3 nM), SW620 (IC₅₀ 4.6 nM), and HT-29 (IC₅₀ 10.1 nM) colorectal cancer cell lines^[1].
p-SCN-Macropa-derived[²²⁵Ac]Ac-macropa-Nimotuzumab potently inhibits viability of 3D spheroids of DLD-1 (IC₅₀ 10.6 nM), SNU-C2B (IC₅₀ 14.7 nM), SW620 (IC₅₀ 19.5 nM), and HT-29 (IC₅₀ 41.5 nM) colorectal cancer cells^[1].
p-SCN-macropa (1 MBq/300 μg; 7 days), as a bifunctional chelator in [²²⁵Ac]Ac-macropa-Trastuzumab (HY-P9907)-PEG₆-DM1, supports high radiochemical purity and excellent in vitro stability in human serum and PBS^[2].
p-SCN-macropa-based [²²⁵Ac]Ac-macropa-trastuzumab-PEG₆-DM1 binds with high affinity to HCC1954 (K_D = 36.98 nM) and JIMT-1 (K_D = 20.16 nM) HER2-positive breast cancer cells, with HER2 density-dependent internalization that is significantly higher in high HER2-density HCC1954 cells^[2].
p-SCN-Macropa (5-10 mg/mL; 90 min at 37°C for conjugation, 5-10 min at room temperature for radiolabeling)-conjugated rosigatamab efficiently chelates ²²⁵Ac at room temperature within 5-10 min^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.